Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report)'s stock price dropped 1.3% during mid-day trading on Friday . The stock traded as low as $1.45 and last traded at $1.47. Approximately 129,515 shares were traded during trading, a decline of 49% from the average daily volume of 253,318 shares. The stock had previously closed at $1.49.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their target price on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 7th.

Repare Therapeutics Stock Down 1.3%

The company has a 50-day simple moving average of $1.26 and a two-hundred day simple moving average of $1.47. The firm has a market cap of $63.05 million, a PE ratio of -0.74 and a beta of 0.85.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Owl Capital Holdings LP boosted its position in Repare Therapeutics by 2.1% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company's stock worth $4,511,000 after purchasing an additional 71,160 shares during the last quarter. Acadian Asset Management LLC boosted its position in Repare Therapeutics by 35.6% in the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock worth $624,000 after purchasing an additional 168,230 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in Repare Therapeutics by 100.0% in the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after purchasing an additional 100,000 shares during the last quarter. Millennium Management LLC boosted its position in Repare Therapeutics by 65.5% in the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company's stock worth $224,000 after purchasing an additional 67,638 shares during the last quarter. Finally, Stifel Financial Corp boosted its position in Repare Therapeutics by 73.1% in the fourth quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock worth $117,000 after purchasing an additional 37,800 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company's stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.